广济药业(000952) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥161,605,183.84, representing a 5.61% increase year-over-year, while the year-to-date revenue reached ¥674,481,519.91, up 41.60% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥4,788,962.79, a decrease of 133.11% year-over-year, and the year-to-date net profit was ¥19,907,205.68, down 73.16% compared to the previous year[5] - Total operating revenue for the third quarter reached CNY 674.48 million, a significant increase of 41.5% compared to CNY 476.33 million in the same period last year[24] - Net profit for the quarter was CNY 18.27 million, a decrease of 74.2% from CNY 70.76 million in the previous year[25] - Total comprehensive income for the third quarter was CNY 18,261,637.36, compared to CNY 70,728,188.49 in the same period last year[26] - Basic earnings per share decreased to CNY 0.0564 from CNY 0.2156 year-over-year[26] Assets and Liabilities - The total assets as of September 30, 2022, were ¥2,351,308,234.63, reflecting a 14.76% increase from the end of the previous year[5] - The company's total assets reached CNY 2.35 billion, up from CNY 2.05 billion year-on-year, reflecting a growth of 14.7%[22] - Current liabilities totaled CNY 597.30 million, an increase of 10.5% from CNY 540.29 million in the previous year[22] - The company’s long-term borrowings increased significantly by 633.98%, reaching ¥252,855,000.00, due to new bank loans obtained during the reporting period[8] - Long-term borrowings rose significantly to CNY 252.86 million, compared to CNY 34.45 million in the same period last year[22] - The company’s total liabilities increased, with accounts payable rising by 28.20% to ¥155,915,677.09, driven by increased material procurement[8] Cash Flow - Cash flow from operating activities showed a net outflow of ¥598,622.65, a decline of 100.85% compared to the previous year, attributed to rising raw material and energy prices[9] - Cash inflow from operating activities increased to CNY 642,729,723.94, up from CNY 507,761,446.92 in the previous year[27] - Net cash flow from operating activities turned negative at CNY -598,622.65, compared to a positive CNY 70,403,789.39 last year[29] - Cash flow from investing activities resulted in a net outflow of CNY -59,583,541.99, worsening from CNY -39,001,358.06 in the previous year[29] - Cash flow from financing activities generated a net inflow of CNY 207,913,854.07, compared to a net outflow of CNY -7,966,789.63 last year[29] - Total cash outflow from operating activities was CNY 643,328,346.59, compared to CNY 437,357,657.53 last year[29] Research and Development - The company experienced a 77.99% increase in R&D expenses, totaling ¥51,573,922.12, due to investments in optimizing the fermentation process for vitamin B2 and other pharmaceutical formulation projects[8] - Research and development expenses increased to CNY 51.57 million, representing an increase of 77.8% compared to CNY 28.98 million last year[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,674[11] - The largest shareholder, Changjiang Industrial Investment Group Co., Ltd., holds 24.84% of shares, totaling 87,592,065 shares[11] - The company reported cash dividends of RMB 0.6 per 10 shares based on a total share capital of 352,648,939 shares for the 2021 annual profit distribution[17] Government Support and Investments - The company received government subsidies amounting to ¥9,646,099.06 year-to-date, which is a 41.33% increase compared to the previous year[8] - A capital increase of RMB 45 million was approved for the wholly-owned subsidiary, Hubei Guangji Pharmaceutical Jikang Pharmaceutical Co., Ltd., to support its diversified business strategy[18] - The company acquired state-owned land use rights totaling 103,100.08 square meters for RMB 56,473,404.54[18] Other Financial Metrics - The company reported a decrease in investment income of 73.72%, totaling ¥4,942,171.01, due to significant fluctuations in profits from its associate company[8] - The company reported a decrease in financial expenses to CNY 7.94 million from CNY 10.83 million, a reduction of 26.7%[25] - The company’s cash and cash equivalents were reported at CNY 919.98 million, an increase of 29.7% from CNY 708.96 million last year[22] - As of September 30, 2022, cash and cash equivalents amounted to RMB 380,002,735.56, an increase from RMB 293,332,160.43 at the beginning of the year[20] - Accounts receivable increased to RMB 199,867,791.31 from RMB 182,981,957.15 at the start of the year[20]